{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:30:52Z","timestamp":1790721052429,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary mitochondrial disorders (PMDs) are a diagnostic challenge for paediatricians, and identification of reliable and easily measurable biomarkers has become a high priority. This study aimed to investigate the role of serum fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15) in children with PMDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed serum FGF21 and GDF15 concentrations by enzyme-linked immunosorbent assay (ELISA) in children with PMDs, patients with non-mitochondrial neuromuscular disorders (NMDs), and aged-matched healthy children, and compared them with serum lactate and ratio of lactate and pyruvate (L\/P). We also evaluated correlations between these biomarkers and the phenotype, genotype, and severity of PMDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median serum GDF15 and FGF21 concentrations were significantly elevated in fifty-one patients with PMDs (919.46 pg\/ml and 281.3 pg\/ml) compared with those of thirty patients with NMDs (294.86 pg\/ml and 140.51 pg\/ml, both\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05) and fifty healthy controls (221.21 pg\/ml and 85.02 pg\/ml, both\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). The area under the curve of GDF15 for the diagnosis of PMDs was 0.891, which was higher than that of the other biomarkers, including FGF21 (0.814), lactate (0.863) and L\/P ratio (0.671). Calculated by the maximum Youden index, the critical value of GDF15 was 606.369 pg\/ml, and corresponding sensitivity and specificity were 74.5and 100%. In the PMD group, FGF21 was significantly correlated with International Paediatric Mitochondrial Disease Scale (IPMDS) score. The levels of GDF15 and FGF21 were positively correlated with age, critical illness condition, and multisystem involvement but were not correlated with syndromic\/non-syndromic PMDs, different mitochondrial syndromes, nuclear DNA\/mitochondrial DNA pathogenic variants, gene functions, or different organ\/system involvement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Regardless of clinical phenotype and genotype, circulating GDF15 and FGF21 are reliable biomarkers for children with PMDs. GDF15 can serve as a screening biomarker for diagnosis, and FGF21 can serve as a severity biomarker for monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2022.851534","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T07:28:37Z","timestamp":1649921317000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["Circulating FGF21 and GDF15 as Biomarkers for Screening, Diagnosis, and Severity Assessment of Primary Mitochondrial Disorders in Children"],"prefix":"10.3389","volume":"10","author":[{"given":"Yi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinfeng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maobin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1016\/S0140-6736(18)30727-X","article-title":"Mitochondrial medicine in the omics era","volume":"391","author":"Rahman","year":"2018","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/ana.24362","article-title":"Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease","volume":"77","author":"Gr\u00e1inne","year":"2015","journal-title":"Ann Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s40142-018-0138-9","article-title":"Mitochondrial disease: advances in clinical diagnosis, management, therapeutic development, and preventative strategies","volume":"6","author":"Muraresku","year":"2018","journal-title":"Curr Genet Med Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"102784","DOI":"10.1016\/j.ebiom.2020.102784","article-title":"Genetics of mitochondrial diseases: Identifying mutations to help diagnosis","volume":"56","author":"Stenton","year":"2020","journal-title":"EBioMedicine."},{"key":"B5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/gim.2014.177","article-title":"Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society","volume":"17","author":"Parikh","year":"2015","journal-title":"Genet Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1042\/EBC20170111","article-title":"Biomarkers for mitochondrial energy metabolism diseases","volume":"62","author":"Boenzi","year":"2018","journal-title":"Essays Biochem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/978-3-662-49410-3_14","article-title":"Workup of the patient with lactic academia","volume":"17","author":"Nyhan","year":"2017","journal-title":"Mitochondr Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ymgme.2012.11.283","article-title":"Role of creatine as biomarker of mitochondrial diseases","volume":"108","author":"Pajares","year":"2013","journal-title":"Mol Genet Metab."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5968","DOI":"10.1210\/jc.2019-00721","article-title":"Hydroxylated long-chain acylcarnitines are biomarkers of mitochondrial myopathy","volume":"104","author":"Vissing","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"B10","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S1474-4422(11)70155-7","article-title":"FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study","volume":"10","author":"Suomalainen","year":"2011","journal-title":"Lancet Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1471-2164-15-91","article-title":"Transcriptomic profiling of TK2 deficient human skeletal muscle suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathies","volume":"15","author":"Kalko","year":"2014","journal-title":"BMC Genomics."},{"key":"B12","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/ana.24506","article-title":"Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders","volume":"78","author":"Yatsuga","year":"2015","journal-title":"ANN Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","volume":"78","author":"Fisher","year":"2016","journal-title":"Annu Rev Physiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"6495","DOI":"10.1007\/s11033-013-2767-0","article-title":"Association of fibroblast growth factor (FGF-21) as a biomarker with primary mitochondrial disorders, but not with secondary mitochondrial disorders (Friedreich Ataxia)","volume":"40","author":"Salehi","year":"2013","journal-title":"Mol Biol Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3390\/jcm6080080","article-title":"Use of FGF-21 as a biomarker of mitochondrial disease in clinical practice","volume":"6","author":"Morovat","year":"2017","journal-title":"J Clin Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cytogfr.2013.05.003","article-title":"The multiple facets of the TGF-\u03b2 family cytokine growth\/differentiation factor-15\/macrophage inhibitory cytokine-1","volume":"24","author":"Unsicker","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.cell.2019.07.033","article-title":"GDF15 is an inflammation-induced central mediator of tissue tolerance","volume":"78","author":"Luan","year":"2019","journal-title":"CELL."},{"key":"B18","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/mus.25364","article-title":"Elevated FGF 21 in myotonic dystrophy type 1 and mitochondrial diseases","volume":"55","author":"Lovadi","year":"2017","journal-title":"Muscle Nerve."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1093\/brain\/awx168","article-title":"Monitoring clinical progression with mitochondrial disease biomarkers","volume":"140","author":"Steele","year":"2017","journal-title":"Brain."},{"key":"B20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1212\/WNL.0000000000000578","article-title":"Serum FGF21 levels in adult m. 3243A>G carriers: clinical implications","volume":"83","author":"Koene","year":"2014","journal-title":"Neurology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/8904_2015_436","article-title":"Serum GDF15 levels correlate to mitochondrial disease severity and myocardial strain, but not to disease progression in adult m. 3243A>G carriers","volume":"24","author":"Koene","year":"2015","journal-title":"JIMD Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1210\/jc.2011-2823","article-title":"Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: the Baltimore Longitudinal Study of Aging","volume":"97","author":"Semba","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1161\/ATVBAHA.113.301599","article-title":"Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors","volume":"33","author":"Chow","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1212\/01.WNL.0000033795.17156.00","article-title":"Diagnostic criteria for respiratory chain disorders in adults and children","volume":"59","author":"Bernier","year":"2002","journal-title":"Jama."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1212\/01.wnl.0000244435.27645.54","article-title":"Mitochondrial disease criteria: diagnostic applications in children","volume":"67","author":"Morava","year":"2006","journal-title":"Neurology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s10545-016-9948-7","article-title":"International paediatric mitochondrial disease scale","volume":"39","author":"Koene","year":"2016","journal-title":"J Inherit Metab Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1371\/journal.pone.0148709","article-title":"GDF15 Is Elevated in Children with Mitochondrial Diseases and Is Induced by Mitochondrial Dysfunction","volume":"11","author":"Montero","year":"2016","journal-title":"PLoS One"},{"key":"B28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/ggi.12724","article-title":"Secreted growth differentiation factor 15 as a potential biomarker for mitochondrial dysfunctions in aging and age-related disorders","volume":"16","author":"Fujita","year":"2016","journal-title":"Geriatr Gerontol Int"},{"key":"B29","doi-asserted-by":"publisher","first-page":"8110","DOI":"10.1007\/s12035-016-0283-7","article-title":"Growth differentiation factor 15 is a novel diagnostic biomarker of mitochondrial diseases","volume":"54","author":"Ji","year":"2017","journal-title":"Mol Neurobiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/acn3.51104","article-title":"Accuracy of FGF-21 and GDF-15 for the diagnosis of mitochondrial disorders: a meta-analysis","volume":"7","author":"Lin","year":"2020","journal-title":"Ann Clin Transl Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.freeradbiomed.2015.03.020","article-title":"Skeletal muscle increases FGF21 expression in mitochondrial disorders to compensate for energy metabolic insufficiency by activating the mTOR\u2013YY1\u2013PGC1\u03b1 pathway","volume":"84","author":"Ji","year":"2015","journal-title":"Free Rad Biol Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1212\/WNL.0000000000003374","article-title":"FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders","volume":"87","author":"Lehtonen","year":"2016","journal-title":"Neurology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1212\/WNL.0000000000002705","article-title":"A comparison of current serum biomarkers as diagnostic indicators of mitochondrial diseases","volume":"86","author":"Davis","year":"2016","journal-title":"Neurology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/cvr\/cvu263","article-title":"Fibroblast growth factor 21 protects the heart from oxidative stress","volume":"106","author":"Planavila","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.molmet.2015.11.002","article-title":"Muscle mitochondrial stress adaptation operates independently of endogenous FGF21 action","volume":"5","author":"Ost","year":"2015","journal-title":"Mol. Metab."},{"key":"B36","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/cen.12095","article-title":"Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives","volume":"78","author":"Woo","year":"2013","journal-title":"Clin Endocrinol (Oxf)."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1194\/jlr.M044784","article-title":"Fibroblast growth factor 21 is induced upon cardiac stress and alters cardiac lipid homeostasis","volume":"55","author":"Brahma","year":"2014","journal-title":"J Lipid Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/annonc\/mdu120","article-title":"GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma","volume":"25","author":"Yang","year":"2014","journal-title":"Ann Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000446586","article-title":"Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: importance of distinction for diagnosis and treatment","volume":"7","author":"Niyazov","year":"2016","journal-title":"Mol Syndromol."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.851534\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T07:28:39Z","timestamp":1649921319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.851534\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":39,"alternative-id":["10.3389\/fped.2022.851534"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.851534","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]},"article-number":"851534"}}